Male Health
New prostate cancer risk prediction tool identifies men at highest risk
Prostate cancer is the fourth most common cancer worldwide and the most common cancer among men in the UK. In…
Tavanta concludes subject enrolment in Phase III prostate cancer trial
Tavanta Therapeutics has concluded subject enrolment in its pivotal Phase III clinical trial of TAVT-45 (abiraterone acetate) granules for oral…
Increase in prostate cancer screening after rollout of revised national guidelines
In May 2018, the US Preventive Services Task Force (USPSTF) published new prostate cancer screening guidelines, which had last been…
Slow progress for male contraceptive trials
Within the pharmaceutical sphere, it is commonly known that the development of reversible male contraception has been extremely difficult. Options…
Astellas-Pfizer’s Xtandi reduces mortality risk in prostate cancer trial
Astellas Pharma and Pfizer have reported that their drug Xtandi (enzalutamide) enhanced overall survival (OS) in the Phase III ARCHES…
Subscribe to our Newsletter
Get industry leading news, data and analysis delivered to your inbox
Pfizer initiates dosing in Phase III prostate cancer drug trial
Pfizer has dosed the first subject in a Phase III TALAPRO-3 clinical trial of oral drug talazoparib plus enzalutamide in…
Telix begins Phase III prostate cancer treatment trial
Telix Pharmaceuticals has begun a Phase III ProstACT clinical trial of its therapy candidate, TLX591 (177Lu-DOTA-rosopatamab), in advanced metastatic castrate-resistant…
Can Merck overcome challenges in an immunologically “cold” tumour with Keytruda for prostate cancer?
Immuno-oncology represents a third major wave of strategies to treat cancer, after chemotherapy and targeted therapy. Some tumours, such as…
AstraZeneca and MSD report positive data from trial of Lynparza
AstraZeneca and MSD have reported positive results from the Phase III PROfound trial evaluating the safety and efficacy of Lynparza…
Sophiris Bio receives positive feedback for prostate cancer trial
Late-stage clinical biopharmaceutical company Sophiris Bio has received positive feedback from the European Medicines Agency (EMA) for the Phase III…